The Efficiency of the EORTC Scoring System for the Prediction of Recurrence and Progression of Non-muscle-invasive Bladder Cancer Treated by Bacillus Calmette-Guerin Immunotherapy

References

• Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49: 466–77
   PubMed Web of Science ®Google Scholar
• Oosterlinck W, Lobel B, Jakse G, et al. Guidelines on bladder cancer. Eur Urol 2002;41: 105–12
   PubMed Web of Science ®Google Scholar
• Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164: 680–4
   PubMed Web of Science ®Google Scholar
• Kurth KH, Denis L, Bouffioux C, et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995;31A: 1840–6
   PubMed Web of Science ®Google Scholar
• Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163: 73–8
   PubMed Web of Science ®Google Scholar
• Solsona E, Iborra I, Dumont R, et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000;164: 685–9
   PubMed Web of Science ®Google Scholar
• Kaasinen E, Rintala E, Hellström P, et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002;42: 167–74
   PubMed Web of Science ®Google Scholar
• Kwak C, Ku JH, Park JY, et al. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer. J Urol 2004;171: 149–52
   PubMed Web of Science ®Google Scholar
• Choi CK, Kim JS, Rim JS. Application of scoring system reflecting various prognostic factors to the prediction of recurrence in superficial bladder carcinoma. Korean J Urol 1999;40: 878–85
   Google Scholar
• Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22: 1435–48
   PubMed Web of Science ®Google Scholar
• Sobin DH, Wittekind CH, eds. TNM Classification of Malignant Tumours, 6th ed. New York: Wiley-Liss; 2002: 199–202
   Google Scholar
• Akaza H, Hinotsu S, Aso Y, et al. Bacillus Calmette–Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder: four-year results. The Bladder Cancer BCG Study Group. Cancer 1995;75: 552–9
   PubMed Web of Science ®Google Scholar
• Akaza H, Koiso K, Ozono S, et al. A clinical study of PMCJ-9 (Bacillus Calmette–Guerin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. Jpn J Clin Oncol 2003;33: 382–90
   PubMed Web of Science ®Google Scholar
• Brausi M, Witjes JA, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011;186: 2158–67
   PubMed Web of Science ®Google Scholar
• Mallett S, Royston P, Waters R, et al. Reporting performance of prognostic models in cancer: a review. BMC Med 2010;8: 21
   PubMed Web of Science ®Google Scholar
• Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. BMJ 2009;338: b605
   PubMed Web of Science ®Google Scholar
• Van Rhijn BWG, Zuiverloon TCM, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non–muscle-invasive bladder cancer. Eur Urol 2010;58: 433–41
   PubMed Web of Science ®Google Scholar
• Hernandez V, De La Pena E, Martin MD, et al. External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. World J Urol. In press. DOI:10.1007/s00345-010-0635-2
   Google Scholar
• Pillai R, Wang D, Mayer EK, Abel P. Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non–muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort. Scientific World J 2011;11: 751–9
   Google Scholar
• Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting non muscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009;182: 2195–203
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49: 466–77
   PubMed Web of Science ®Google Scholar
• Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54: 303–14
   PubMed Web of Science ®Google Scholar
• Han RF, Pan JG. Can intravesical Bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67: 1216–23
   PubMed Web of Science ®Google Scholar
• Shelley MD, Wilt TJ, Court J, et al. Intravesical Bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93: 485–90
   PubMed Web of Science ®Google Scholar
• Bohle A, Jocham D, Bock PR. Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169: 90–5
   PubMed Web of Science ®Google Scholar
• Friedrich MG, Pichlmeier U, Schwaibold H, et al. Long term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007;52: 1123–30
   PubMed Web of Science ®Google Scholar